Literature DB >> 10101381

Voluntary newborn HIV-1 antibody testing: a successful model program for the identification of HIV-1-seropositive infants.

E J Abrams1, D A Bateman.   

Abstract

Harlem Hospital in New York City has one of the highest HIV-1 newborn seroprevalence rates in the United States. We report the results of a program introduced in 1993 and designed to identify HIV-1-seropositive (HIV+) newborns at birth. All new mothers, independent of risk, received HIV counseling that emphasized the medical imperative to know the infant's HIV status as well as their own. Consent was obtained to test the infant; discarded cord blood samples were tested by enzyme-linked immunosorbent assay (ELISA), and when positive, Western Blot confirmation. We compared the number of HIV+ infants identified through voluntary testing with the number reported by the anonymous New York State Newborn HIV Seroprevalence Study. In 1993, 97.8% (91 of 93) of the number of HIV+ infants identified by the anonymous testing were identified through voluntary maternal and newborn testing programs. Eighty-five HIV+ infants were identified before nursery discharge: 50% (42/85) through newborn testing; 14% (12/85) through prenatal testing; 13% (11/85) presented to care knowing their status; 23% (20/85) were known because of a previous HIV+ child. Six additional HIV+ children were diagnosed after hospital discharge (mean age, 5.5 months; range 1.5 through 17 months); four presented with symptomatic disease. The optimal time for identification of the HIV+ pregnant woman is before or during pregnancy, but when this does not occur, voluntary newborn testing can identify many HIV+ infants who would otherwise be discharged undiagnosed from the nursery.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 10101381      PMCID: PMC2359450     

Source DB:  PubMed          Journal:  Bull N Y Acad Med        ISSN: 0028-7091


  10 in total

1.  HIV seroprevalence in newborns in New York State.

Authors:  L F Novick; D Berns; R Stricof; R Stevens; K Pass; J Wethers
Journal:  JAMA       Date:  1989 Mar 24-31       Impact factor: 56.272

2.  Routine prenatal screening for HIV infection.

Authors:  M Barbacci; J T Repke; R E Chaisson
Journal:  Lancet       Date:  1991-03-23       Impact factor: 79.321

3.  Newborn human immunodeficiency virus testing in New York: a legislative quandary.

Authors:  D A Bateman; A Cooper; E J Abrams
Journal:  Arch Pediatr Adolesc Med       Date:  1995-05

4.  Ethical challenges posed by zidovudine treatment to reduce vertical transmission of HIV.

Authors:  R Bayer
Journal:  N Engl J Med       Date:  1994-11-03       Impact factor: 91.245

5.  Serosurvey of human immunodeficiency virus infection in parturients. Implications for human immunodeficiency virus testing programs of pregnant women.

Authors:  S Landesman; H Minkoff; S Holman; S McCalla; O Sijin
Journal:  JAMA       Date:  1987-11-20       Impact factor: 56.272

6.  Maternal-newborn human immunodeficiency virus infection in Harlem.

Authors:  S W Nicholas; D A Bateman; S K Ng; T Dedyo; M C Heagarty
Journal:  Arch Pediatr Adolesc Med       Date:  1994-08

7.  Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group.

Authors:  E M Connor; R S Sperling; R Gelber; P Kiselev; G Scott; M J O'Sullivan; R VanDyke; M Bey; W Shearer; R L Jacobson
Journal:  N Engl J Med       Date:  1994-11-03       Impact factor: 91.245

8.  Routine antepartum human immunodeficiency virus infection screening in an inner-city population.

Authors:  M K Lindsay; H B Peterson; T I Feng; B A Slade; S Willis; L Klein
Journal:  Obstet Gynecol       Date:  1989-09       Impact factor: 7.661

9.  Factors predictive of maternal-fetal transmission of HIV-1. Preliminary analysis of zidovudine given during pregnancy and/or delivery.

Authors:  P J Boyer; M Dillon; M Navaie; A Deveikis; M Keller; S O'Rourke; Y J Bryson
Journal:  JAMA       Date:  1994 Jun 22-29       Impact factor: 56.272

10.  Efficacy of antenatal zidovudine in reducing perinatal transmission of human immunodeficiency virus type 1. The New York City Perinatal HIV Transmission Collaborative Study Group.

Authors:  P B Matheson; E J Abrams; P A Thomas; M A Hernán; D M Thea; G Lambert; K Krasinski; M Bamji; M F Rogers; M Heagarty
Journal:  J Infect Dis       Date:  1995-08       Impact factor: 5.226

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.